Showing results (101-110 of 109) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancerUrsula A Matulonis, Neil S Horowitz, Susana M Campos, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 27, 2013
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancerJose Alejandro Rauh-Hain, Stephanie H Guseh, Katharine M Esselen, et al.Gynecologic Oncology|July 10, 2021
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancerCarolyn N Krasner, Susana M Campos, Chantay L Young, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumorsRichard T Penson, Don S Dizon, Stephen A Cannistra, et al.Gynecologic Oncology|February 16, 2019
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian originC N Krasner, C Castro, R T Penson, et al.Gynecologic Oncology|March 27, 2016
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancerR T Penson, E Sales, L Sullivan, et al.Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 26, 2014
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II studyJonathan S Berek, Robert P Edwards, Lynn P Parker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancerBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.Pageof 11